Merck delays Zocor/niacin combo
Executive Summary
Merck will not file its fixed-dose combo drug MK-0524B, combining Zocor (simvastatin) and MK-0524A (extended-release niacin and a flushing inhibitor), in 2007 as planned due to formulation problems, the company announces Sept. 29. The company will continue its late-stage clinical program to support the regulatory filing for the LDL-lowering/HDL-raising triple combination, but it did not announce a new timeline for NDA submission. The firm still expects to file MK-0524A in 2007. Merck has continuously said that neither product will affect Vytorin (simvastatin/ezetimibe), which it co-markets with Schering-Plough (1"The Pink Sheet" Jan. 16, 2006, p. 12)...
You may also be interested in...
Merck agent reduces niacin flushing
Data on Merck's MK-0524, an investigational DP1-receptor antagonist, shows a reduction in flushing in dyslipidemia patients on extended-release niacin. In data presented Nov. 16 at the American Heart Association's Scientific Sessions in Chicago, 37% of patients taking MK-0524 plus niacin reported flushing compared to 61% of patients treated with niacin alone. Merck is in clinical trials for MK-0524a, a fixed-dose combination of niacin and MK-0524 (1"The Pink Sheet" Oct. 2, 2006, In Brief)...
Joint Venture On The Rocks? Schering Looks To Compete With Partner Merck
Schering-Plough is exploring opportunities to add Zetia (ezetimibe) to an agent that would give the treatment an entrance into the growing HDL-cholesterol category
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.